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Abstract
Electrochemiluminescent (ECL) arrays containing polymer ([Ru(bpy)2(PVP)10]2+, PVP =
polyvinylpyridine), DNA, and selected enzymes were employed to elucidate cytochrome (cyt)
P450 dependent metabolism of the tobacco specific carcinogen, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK). Bioactivated NNK metabolites formed upon H2O2-enzymatic
activation were captured as DNA adducts and detected simultaneously from 36 spot arrays by
capturing and quantifying emitted ECL with an overhead CCD camera. Increased ECL emission
was dependent on NNK exposure time. Of the enzymes tested, the activity toward NNK
bioactivation was cyt P450 1A2 > 2E1 > 1B1 ≈ chloroperoxidase (CPO) > myoglobin (Mb) in
accordance with reported in vivo studies. Cyt P450/polyion films were also immobilized on 500
nm diameter silica nanospheres for product analysis by LC-MS. Analysis of the nanosphere film
reaction media provided ECL array validation and quantitation of the bioactivated NNK
hydrolysis product 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) confirming production of reactive
metabolites in the films. Chemical screening in this fashion allows rapid clarification of enzymes
responsible for genotoxic activation as well as offering insight into cyt P450-related toxicity and
mechanisms.
Introduction
Metabolic and toxicity testing of chemicals and chemical mixtures designed for
pharmaceutical, industrial, or personal use is a major undertaking because of the numbers of
compounds, assay times, instrumental costs, and sometimes poor correlation of in vitro data
to in vivo response.1,2 For compounds designed for human ingestion, like drugs and food
additives, knowledge of the metabolic enzymes involved is paramount.3 Often, it is through
the metabolic process that toxicity is imparted to an otherwise benign chemical compound.4
This process is termed “bioactivation” and must be discovered before a compound is
released to the public.4,5 Undiscovered toxic metabolites have in part lead to highly
publicized pharmaceutical side reactions that can eventually lead to large scale recalls
costing huge monetary sums, and sometimes unwarranted mortality.5,6
†Electronic supplementary information (ESI) available: Additional experimental details and Fig. S1–S3.
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From a non-pharmaceutical standpoint, diseases have been hypothesized to originate from
exposure to ubiquitous compounds in the everyday environment, including those compounds
in the food supply,7 drinking water,8 and air.9 However, a significant level of controversy
exists in detailing what is actually toxic upon human consumption or exposure.10–12
Certainly, some of this controversy stems from genetic heterogeneity that predisposes
certain individuals or populations to xenobiotic induced diseases based on slight differences
altering the delicate balance between metabolism and DNA repair pathways.13,14 The
enzymes predominately responsible for the primary metabolism of xenobiotics are the
monooxygenase cytochrome (cyt) P450s present in all human tissues.5 Therefore, it is
necessary to rapidly and affordably elucidate the P450 isoforms responsible for xenobiotic
metabolism of chemical compounds in order to help alleviate any existing toxicity
controversy and rapidly elucidate pathways of toxic metabolite formation.
We have previously demonstrated a high-throughput array-based metabolism assay designed
to show enzyme–substrate specificity involving reactive metabolite detection via a DNA
damage endpoint.15–17 Here, multiple spots constructed layer by layer (LbL) featuring of a
DNA-reactive ruthenium polyvinylpyridine (RuPVP) electrochemiluminescent (ECL)
generating polymer18 along with DNA and cyt P450 isozymes of interest are immobilized
on a large 1 in2 graphite block. The substrate reaction occurs after peroxide activation of the
cyt P450s facilitating ferryloxo radical formation19 to produce identical products vis-à-vis
the natural NADPH–reductase activation cycle.20 After completion of the reaction, the
electrode block is transferred into a dark box equipped with an overhead CCD camera that
can visualize the ECL generated from the interaction of the RuPVP and DNA from each
spot simultaneously upon the application of an external potential. ECL increase is
proportional to the amount of reactive metabolite induced DNA damage.15 Higher catalytic
turnovers and ECL outputs are due to the ease of ruthenium access to guanine bases in DNA
slightly distorted by adduct formation of other bases with the metabolites.16 The relative
increase in DNA damage is proportional to the amount of DNA-reactive metabolite
generated and related to enzyme–substrate specificity. Validation and quantification of the
sensor response can be achieved employing synergistic LC-MS methods where similar
layered films can be immobilized on 500 nm silica nanoparticles (nanoreactors).15,17,21
Upon exposure to similar reaction conditions, reactive metabolites and metabolite–DNA
adducts can be identified and their rates of formation compared to the increase of ECL
response vs. time.
Cigarettes offer an excellent example of a complex ubiquitous chemical mixture as a source
of etiolic cancer agents toward several different tissues.10,11,22,23 Over 4800 compounds
exist in cigarette smoke, the most carcinogenic of which are the groups of polycyclic
aromatic hydrocarbons (PAHs)24,25 and nitrosamines (N-nitroso compounds).26 The toxicity
of these compounds once ingested comes from their bioactivation by metabolic enzymes,
primarily cyt P450s, to highly reactive forms.27 In this fashion, PAHs are oxidized by cyt
P450 family 1 enzymes to ultimate carcinogens via a number of routes.15,26,28,29N-Nitroso
compounds are predominately hydroxylated at the α-methylene or methyl positions next to
the nitroso moiety, resulting in an unstable species that enters into a variety of reactive
forms that can potentially adduct DNA.30 A simplified bioactivation pathway is summarized
in Scheme 1 using the N-nitroso ketone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK), as an example.
NNK is important due to its predominant presence in cigarettes, making it a potent tobacco
specific carcinogen.30 Furthermore, NNK is of primary interest in this family of tobacco
specific nitrosamines due to its increased levels of toxicity compared to related analogues
present in tobacco.30 Methods to determine enzymatic specificity for the substrates in
question have often employed solution based microsomal31 or reconstituted purified enzyme
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systems32 that can offer the desired information, but are also time consuming and costly
owing to the instrumentation and substrate and/or enzyme amounts needed. Herein we
demonstrate the utility of ECL arrays to elucidate the specificity of different cyt P450s, and
to identify the metabolites of NNK using a selection of metabolic liver and lung cyt P450s
along with control enzymes with peroxidase activity.
Experimental section
Materials
Calf thymus double stranded DNA, type I, 41.9% G/C (DNA), chloroperoxidase (CPO),
myoglobin (Mb), poly(diallyldimethylammonium chloride) (PDDA, a polycation), and
poly(styrenesulfonate) (PSS, a polyanion) were purchased from Sigma. 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-hydroxy-1-(3-pyridyl)-1-
butanone (HPB) were obtained from Toronto research chemicals (North York, ON, Canada).
Cytochrome (cyt) P450 enzymes 1A2 (MW 52 000),33 2E1 (MW 52 000),34 and 1B1 (MW
52 000)35 were expressed from DH5α Escherichia coli containing the proper cDNA, and
were isolated and purified according to the referenced procedures. The concentration of the
expressed P450s was assayed by the Omura and Sato method.36 The activity of the
purchased CPO was assayed by a N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD)
colorimetric assay (Fig. S1, ESI†).37 The ECL polymer [Ru(bpy)2(PVP)10](ClO4)2 (RuPVP)
was prepared following established literature protocols.18,38,39 All other chemicals were
reagent grade.
ECL array fabrication
DNA/RuPVP/enzyme films for ECL arrays (6 × 6 spots) were constructed on a conducting
basal plane pyrolytic graphite (PG) block (Advanced Ceramics, 2.5 cm2 × 1 cm) by the LbL
electrostatic assembly method similar to that described previously.15,19,40 The adsorbed
layers were rinsed with water between adsorption steps to remove weakly adsorbed material.
Film architectures expressed as adsorbed layer order for ECL arrays were DNA(/RuPVP/
DNA)4(/enzyme/DNA)2 denoted as DNA/RuPVP/enzyme (where enzyme = cyt P450 1A2,
2E1, or 1B1, CPO or Mb). The concentrations of solutions used were as follows: 2 mg mL−1
DNA in 10 mM Tris buffer with 50 mM NaCl, pH 7.1, 1 mg mL−1 RuPVP (88% H2O–12%
ethanol), 1 mg mL−1 RuPVP (50% H2O–50% ethanol), myoglobin (3 mg mL−1, 10 mM
acetate buffer, pH 4.5), cyt P450 1A2, 1B1, and 2E1 (1 mg mL−1, 50 mM potassium
phosphate buffer, pH 7.0), CPO (1 mg mL−1, 10 mM acetate buffer, pH 4.5). Each spot had
a final area of 0.04 cm2.
Incubation of ECL array spots with procarcinogen
Safety note: NNK and its metabolites are suspected human carcinogens. All procedures were
done while wearing gloves, and under closed hoods. Film spots were exposed to 1 μL of 1
mM NNK and 1 mM H2O2 in 50 mM acetate buffer, pH 5.5 for different times at 37 °C.
Upon completion of the substrate exposure, the array was rinsed in water to stop the
reaction. Control array spots were incubated either in 1 mM NNK or 1 mM H2O2 under the
same conditions.
Electrochemiluminescence (ECL)
The ECL detection method is same as that described elsewhere.15 Upon reaction completion
and rinsing, the array electrode block was placed in a 100 mL beaker filled to ~50 mL with
10 mM sodium acetate buffer + 0.15 M NaCl, pH 5.5, and was placed in the gel
documentation dark box (SynGene ChemiGeniusQ, Fredrick, MD) for light acquisition by
the CCD camera (QI Cam (Q-Imaging), 12-bit (0–4095 greyscales), 10 000 electron linear
full well capacity, 35% QE at 600 nm). ECL was produced upon application of +1.25 V (CH
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Instruments 1232, Austin, TX) vs. Ag/AgCl for 20 s, and a signal was acquired in pixel
binning high sensitivity mode. Data analysis and quantification were done using GeneSnap
and GeneTools software provided by SynGene (Cambridge, UK, 2005). Faux color was
added to the b/w CCD image using Irfanview (Ver. 4.20, Irfan Skiljan, Vienna, 1996–2008)
and the included Adobe8F filters followed by .tif file and additional color enhancements
using Photoshop CS software. Added color is defined by user preferences, and is not
absolute.
Nanoreactor fabrication
Films were formed on hydroxylated SiO2 (Polysciences, Inc., Warrington, PA, 500 nm dia.)
nanoparticles using a previously established protocol.21 SiO2/PDDA/PSS/enzyme [enzyme
= cyt P450 1A2/2E1, or CPO or Mb] films were incubated in stirred solutions containing 1
mM of each NNK and H2O2 in 50 mM acetate buffer, pH 5.5 for 10 min at 37 °C. The
reaction was stopped via centrifugation, and the supernatant was analyzed using capillary
LC-MS to identify the major 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) hydrolyzed
metabolite. HPB quantification was performed after construction of a calibration plot using
commercially available HPB.
Capillary LC-MS
A trapping column (Atlantis, dC18, 23.5 mm, 0.18 mm, I.D. 5 μm particle size) and the
analytical column (Atlantis, dC18, 150 mm, 300 μm, I.D. 5 μm particle size) were from
Waters (Milford, MA). The capillary LC was equipped with a photo diode array detector
(scanning wavelengths from 200–450 nm). A 10 μL sample injection for each analysis was
loaded into the trapping column at a flow rate of 4.25 μL min−1 and washed with water for 1
min at 10 μL min−1. The trapped metabolite and substrate were then back-flushed from the
trapping column onto the analytical column at 4.25 μL min−1 using the following elution
gradient: 5 min 10% B, 5 min 10% to 30% B, 30 min 30% B, 5 min 30% to 10% B, 5 min
10% B (A, 10 mM acetate buffer, pH 5.5; B, methanol). Electrospray ionization mass
spectrometry (ESI-MS) employed a Micro-mass Quattro II (Beverly, MA) operated in the
positive ion mode (ESI†). The following conditions were used: cone voltage = 15 V,
collision energy = 20 eV and collision gas (Ar) pressure = 5 × 10−3 mbar. The metabolites
were analyzed by total ion scan (TIC).
Results
Fig. 1 shows a reconstructed array demonstrating the ECL response from the DNA/RuPVP/
enzyme films upon NNK–H2O2 exposure for the denoted times (seconds). The ECL is
generated upon application of +1.25 V vs. Ag/AgCl, which oxidizes the RuII centers in the
polymer to RuIII. The oxidized RuIII centers interact with the guanines in the DNA films to
eventually produce an excited RuII* state that emits ECL upon relaxation to the original RuII
form. The ECL increases concomitant with NNK reaction time compared to its initial
baseline (i.e. no damage, 0 s) due to the enzymatic bioactivation of NNK producing reactive
electrophilic species that diffuse through the films to form helix distorting DNA adducts on
nucleophilic DNA. This distortion allows the closer approach of an electrode-oxidized RuIII
center to exposed DNA bases in the film, and a kinetically faster reaction producing
increased amounts of ECL.18 In this fashion, the sensor will detect any adduct that results in
double helix distortion, not just isolated (i.e. N7 guanine) positional isomers.17a Similar
voltammetric guanine detection has been described by Thorp et al. employing soluble
Ru(bpy)2+/3+.16,41
Array reconstruction in this manner allows for a clear qualitative assessment of the enzymes
that are active in the NNK reaction. The important aspect to consider when using the array
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to discern the enzymes that are more active toward a particular tested substrate is the change
in ECL, and that from the analytical spots is compared to the respective zero second
exposure spots as an internal standard. In this fashion, compensation for any inter-
experimental fluctuation in light output is achieved.15 The sensor has the ability to
discriminate enzymes active toward a particular substrate vs. the ones that exhibit more
sluggish reaction rates. From the figure, it is clear that both cyt P450 1A2 and 2E1 films
exhibit the most ECL change over the exposure time range studied; therefore, these two
enzymes are more active and specific toward NNK bioactivation whereas the other P450
isoform, 1B1, and the model oxidases, CPO and Mb, demonstrate no significant ECL
increase, which equates to muted NNK specificity. Mb in fact showed absolutely no ECL
flux across the studied time range, which is consistent with our earlier work concerning the
lack of specificity of this enzyme for N-nitroso compounds.17 Controls for these
experiments have been described previously15,17 and consisted of both an unreacted array
(i.e. enzyme spots exposed to no NNK or H2O2) as well as an array exposed to an individual
member of the damage cocktail (i.e. only NNK or H2O2). The ECL response under these
control conditions does not change appreciably, denoting that the enzymes must be activated
by H2O2, and no other aspects of the reaction or experimental setup are accountable for the
ECL flux (data not shown).
Fig. 2 is the quantitative representation of Fig. 1 raw data results where the percent (%) ECL
change vs. NNK–H2O2 reaction time is plotted for each enzyme film. The percent ECL
change over reaction time was measured relative to each enzyme 0 s exposure spot. Initial
slopes of the data plotted in Fig. 2 are indicative of enzyme-substrate turnover, as validated
by LC-MS experiments.21b Again, cyt P450 1A2 was the most active of the tested enzymes
toward NNK bioactivation into reactive electrophilic intermediates. Cyt P450 2E1 showed
intermediate activity toward NNK, while cyt P450 1B1 and CPO showed negligible activity
in the studied time period. The results showing that cyt P450 1A2 and 2E1 are the most
active toward NNK activation are consistent with previously published data showing that
these enzymes play a significant role in the metabolism of this xenobiotic, which is
discussed further below. NNK is also known to be metabolized in the lungs and respiratory
tract organs and cyt P450 1B1 is an extrahepatic isoform found in those locales. The lack of
ECL signal, however, suggests that this enzyme plays a very small role in any NNK
activation in vivo. As stated previously, Mb demonstrated an ECL% increase slope
approaching 0 (error bars ~ ±5%); therefore, we did not involve that data in further
statistical analysis. In addition, square wave voltammetry19 was performed employing single
electrodes with identical DNA/RuPVP/enzyme layers to verify the ECL response. Indeed,
cyt P450 1A2 showed a similar increase in the voltammetric response (higher peak current),
while cyt P450 1B1, CPO, and Mb films showed very little change over the studied reaction
period (Fig. S2, ESI†).
Table 1 couples the ECL data and the enzyme surface coverage amounts from each film to
summarize relative enzyme turnover values for NNK metabolism. The enzyme surface
coverage (Γ) for each enzyme film was obtained from quartz crystal microbalance (QCM)
studies (Table S1, ESI†). Accounting for Γ allows for an accurate view of the actual enzyme
activity. Consistent with Fig. 1 and 2, cyt P450 1A2 indeed shows the highest NNK turnover
response. T-tests at the 95% confidence level elucidated that cyt P450 1A2 exhibited the
largest statistically significant NNK turnover value, followed by cyt P450 2E1. Similar tests
showed that there was an insignificant difference between cyt P450 1B1 and CPO toward
NNK bioactivation despite differences in raw array ECL percentage increases. This is due to
the G correction factor accounting for the increased amount of P450 1B1 vs. CPO present in
each DNA/RuPVP spot.
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In order to couple the ECL sensor with an absolute quantitative output, LC-MS methods
were employed to study the metabolic output by immobilizing similar films on 500 nm dia.
silica nanospheres (nanoreactors). Fig. 3 shows LC chromatograms and mass spectra
monitoring HPB production from cyt P450 1A2, cyt P450 2E1, and CPO nanoreactor films
after 10 min NNK–H2O2 exposure. HPB is a hydrolyzed NNK metabolite that results from
the conversion of enzyme produced α-hydroxylated NNK into reactive intermediates that
are attacked by the nucleophilic aqueous solvent forming an alcohol (Scheme 1). Therefore,
HPB presence indicates that reactive NNK metabolites are being generated enzymatically.
Fig. 3a shows that the production of HPB is clearly evident from the nanoreactors containing
cyt P450 1A2 and 2E1, while it is absent upon inclusion of the CPO, consistent with the
ECL array data. Cyt 1B1 films exhibited similar responses to those of CPO. HPB from these
films is most likely produced at levels lower than the limits of UV detection. Fig. 3b and c
demonstrates the MS spectra from the TIC chromatogram for the two different peaks in Fig.
3a, which exhibit m/z consistent with newly produced HPB (Fig. 3b) and unreacted NNK
(Fig. 3c), respectively. Qualitatively, the cyt P450 1A2 nanoreactor HPB peak area in Fig.
3a approximately doubles that from cyt P450 2E1 films, and calibration curve quantification
verifies this observation (Fig. S3, ESI†).
We previously utilized the nanoreactor platform to detect and elucidate the DNA adducts
that were being formed in the immobilized films. We showed that cyt P450 2E1 produced
reactive NNK metabolites that led to labile DNA adducts with m/z 299 that increased in a
linear fashion over reaction time.21a Upon analysis employing tandem MS, we showed that
these adducts fragmented to m/z 152, characteristic of NNK–guanine adducts fragmenting to
guanine. Overall, the data were consistent with pyridyloxobutylation of guanine from the
bioactivation by cyt P450 2E1.21a Taken as a whole, this demonstrates that the increasing
production of HPB in the films is indicative of the increasing population of reactive
metabolites in the films leading to increasing amounts of DNA adducts.
Table 1 also summarizes the absorbance peaks from the LC chromatograms based on the
calibration curve plot where 0.72 and 0.36 nmol HPB were produced in 10 min,
respectively, from cyt P450 1A2 and cyt P450 2E1 films. As Table 1 describes, the LC-MS
and ECL array data both show an approximate 50% decrease in enzymatic turnover when
going from cyt P450 1A2 to cyt P450 2E1 films, which demonstrates the excellent synergy
by both layered film methods to rapidly ascertain and confirm enzyme–substrate specificity.
Discussion
Both ECL array and LC-MS methods employed in this study clearly demonstrate the NNK
metabolism differences between the different cyt P450 enzymes. Of the enzymes employed,
cyt P450 1A2 exhibited higher specificity toward NNK bioactivation for DNA damage
followed by cyt P450 2E1, which was shown to be approximately half as active as cyt P450
1A2 toward NNK metabolism. None of the other enzymes studied here, including cyt P450
1B1, showed preference toward activation of this cancerous compound.
It has been known for some time that the two isoforms (1A2, 2E1) show a capacity toward
NNK bioactivation both in vitro31,32,42 and in vivo.43,44 The sensor results here showing
that cyt P450 1A2 is approximately two times more reactive toward NNK bioactivation for
DNA damage than cyt P450 2E1 agree well with previous in vitro solution studies. Smith et
al. employed purified enzymes or heterologously expressed enzymes from different cell
lines to study this reaction. Their results have shown that NNK is converted to the keto
alcohol (HPB) by cyt P450 1A2 with kcat/Km values typically 3 to 10 times greater than cyt
P450 2E1.32,42 Therefore, on a qualitative level, our results correlate well with these
previous in vitro kinetic studies showing that cyt P450 1A2 exhibits at least twice the
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specificity toward NNK bioactivation compared to cyt P450 2E1. Any quantitative
deviations (i.e. differences in rates, specificity, etc.) from previous reports and our results
described herein are likely to stem from the different metabolic system used.15 Here we
employed purified enzymes activated via peroxide shunt, which has been shown to produce
identical metabolites in varying proportions vs. NADPH activation with P450 reductase.20
Other systems (i.e. reconstituted lipid, microsomal, membrane, whole cell, etc.) typically
generate differences in the Michaelis–Menten parameters.45
It is not surprising that cyt P450 1B1 in our sensor did not bioactivate NNK very well as it
shows preference for larger aromatic molecules, such as PAHs.27b However, no report to our
knowledge has ever suggested that NNK could be metabolized by cyt P450 1B1; therefore,
at the very least the use of this enzyme acts as a negative control and confirms previous
literature accounts summarizing the enzymes active in the bioactivation of this molecule.30b
Overall, depending on the expression system used in addition to the reconstitution
parameters, cyt P450 1A2 shows enhanced specificity toward NNK activation compared to
cyt P450 2E1.
ECL results can shed some light on the actual in vivo toxicity of this molecule. NNK is
known to be carcinogenic toward not only the respiratory tract organs but the liver and
pancreas as well.30,46 Cyt P450 family 2A enzymes are predominantly active in NNK lung
metabolism,47 but cyt P450 1A2 and cyt P450 2E1 are predominantly located in the liver.27b
These two isoforms have been implicated in the complex cancer etiology leading from
increasing amounts of NNK metabolites damaging DNA to neoplasia in the liver.31,48 Also,
these cyt P450 isoforms are inducible through ingestion of other xenobiotics—i.e. alcohol
consumption promoting increased cyt P450 2E1 expression.49 In this vein, hamsters that had
been exposed to NNK had a dramatic shift in the locale of new cancerous tissue from lung to
pancreas upon additional exposure to alcohol.50 While this xenobiotic synergy is not
completely understood, one explanation cites the increased quantity of NNK metabolites
from the induced cyt P450 2E1 enzymes.43
The chromatographic and ECL methods offered congruent results as both showed that NNK
was two times more reactive after interaction with cyt P450 1A2 compared to cyt P450 2E1.
The similarity in the LC-MS HPB detection result compared to the ECL turnover values
verifies that the ECL signal increase is due to reactive metabolite formation in the films that
manifest as detectable DNA adducts. Therefore, this platform offers more than a DNA
damage sensor. Rather, it can act as a platform from which toxic metabolite production can
be monitored. We previously exhibited this kind of method synergy employing purified
enzymes15 and membrane and/or microsomal enzymes.17 In the previous report employing
purified enzymes, we showed that cyt P450 1B1 was highly specific toward activation of
benzo[a]pyrene (B[a]P) followed by cyt P450 1A2 and 2E1. Here, using a different class of
molecule, an opposite bioactivation order was obtained, but one that is consistent with
previous metabolic studies in the literature. This further demonstrates the utility of the ECL
array to be able to rapidly detect enzymatic specificity for a number of potentially hazardous
compounds and a range of enzymes. In addition, results also suggest that the ECL/LC-MS
method synergy shows great promise for future high-throughput metabolism and toxicity
investigations of potential drugs and environmental pollutants.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 1. Cyt P450 catalyzed bioactivation of NNK.30
NNK (1) undergoes α-hydroxylation (2) by various cyt P450 isoforms in vivo followed by
loss of formaldehyde to yield 4-oxo-4-(3-pyridyl)-1-butane-diazohydroxide (3). 3 is a short
lived species that rearranges into highly electrophilic intermediates that are attacked by
nucleophilic guanine bases in DNA yielding 7-[4-oxo-4-(3-pyridyl)but-1-yl]Gua (4) or O6-
[4-oxo-4-(3-pyridyl)but-1-yl]Gua adducts (5) among others. In the absence of DNA, water
attacks the electrophilic intermediates yielding the metabolite 4-hydroxyl-1-(3-pyridyl)-1-
butanone (HPB, 6).
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Fig. 1.
Reconstructed array data showing the ECL response from the different DNA/RuPVP/
enzyme films exposed to the 1 mM NNK-1 mM H2O2 cocktail for the denoted times (s).
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Fig. 2.
Relative ECL percentage increase vs. NNK-H2O2 reaction time for the enzyme films
depicted in Fig. 1.
Krishnan et al. Page 13
Mol Biosyst. Author manuscript; available in PMC 2012 October 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 3.
(a) LC chromatograms showing the UV response from the nanoreactor enzyme films upon
reaction with NNK and H2O2 for 10 min. Control is a 1A2 enzyme film exposed to NNK
without the additional H2O2. (b) Mass spectrum of Peak A in (a) demonstrating the presence
of material consistent with HPB. (c) Mass spectrum of Peak B in (a) showing the presence
of unreacted NNK.
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Table 1
Summary of enzyme surface coverage and NNK–enzyme turnover values
Enzyme film Total surface coverage/pmol
cm−2 Initial slope
a ECL array turnover valueb/cm2 (pmol
enzyme)−1 min−1 LC-UV HPB quant.
c/nmol
1A2 62(±10) 39.2(±3.70) 0.61(±0.11) 0.72(±0.05)
2E1 54(±8.0) 16.2(±3.10) 0.30(±0.07) 0.36(±0.03)
1B1 52(±6.0) 8.43(±1.45) 0.16(±0.03) n.d.
CPO 22(±2.0) 3.42(±1.46) 0.16(±0.07) n.d.
a
From Fig. 2 (% ECL increase min−1)
b% ECL increase.
c
Detected after 10 min reaction.
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